Furthermore, we report our novel analysis in associating genomic DNA methylation with levels of reproductive hormones in PCOS patients including estradiol (E2), luteinising hormone (LH), follicle stimulating hormone (FSH), progesterone (P), thyroid stimulating hormone (TSH), prolactin (PRL), testosterone (TST), which could reveal the molecular basis of the observed clinical heterogeneity in PCOS patients. This evidence concerns the gene BRD2 and polycystic ovary syndrome.